SNAP-25 Protein

SNAP-25 (Synaptosomal-Associated Protein 25)

Introduction

SNAP-25 (Synaptosomal-Associated Protein 25) is a 206-amino acid peripheral membrane protein that functions as the primary t-SNARE (target SNAP receptor) in the synaptic vesicle fusion machinery. Together with [syntaxin-1](/proteins/stx1a-protein) and [VAMP2](/proteins/vamp2-protein), SNAP-25 forms the core SNARE complex that drives Ca²⁺-triggered neurotransmitter release. SNAP-25 is anchored to the presynaptic plasma membrane via palmitoylation of four cysteine residues (Cys 85, 88, 90, 92) and lacks a transmembrane domain, making it unique among SNARE proteins. SNAP-25 dysfunction is implicated in Alzheimer's disease, Parkinson's disease, ALS, and schizophrenia[@sutton1998].

SNAP-25 (Synaptosomal-Associated Protein 25)

Introduction

SNAP-25 (Synaptosomal-Associated Protein 25) is a 206-amino acid peripheral membrane protein that functions as the primary t-SNARE (target SNAP receptor) in the synaptic vesicle fusion machinery. Together with [syntaxin-1](/proteins/stx1a-protein) and [VAMP2](/proteins/vamp2-protein), SNAP-25 forms the core SNARE complex that drives Ca²⁺-triggered neurotransmitter release. SNAP-25 is anchored to the presynaptic plasma membrane via palmitoylation of four cysteine residues (Cys 85, 88, 90, 92) and lacks a transmembrane domain, making it unique among SNARE proteins. SNAP-25 dysfunction is implicated in Alzheimer's disease, Parkinson's disease, ALS, and schizophrenia[@sutton1998].

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#f0f0f0;">SNAP-25 Protein Overview</th></tr>
<tr><td><strong>Protein Name</strong></td><td>Synaptosomal-Associated Protein 25</td></tr>
<tr><td><strong>Gene</strong></td><td>[SNAP25](/genes/snap25)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td><a href="https://www.uniprot.org/uniprot/P60880" target="_blank">P60880</a></td></tr>
<tr><td><strong>Chromosomal Location</strong></td><td>20p12.1</td></tr>
<tr><td><strong>PDB Structures</strong></td><td>1KTH, 1X5F, 3IP4</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>~25.6 kDa</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Presynaptic plasma membrane (palmitoylated)</td></tr>
<tr><td><strong>Protein Family</strong></td><td>SNARE family (Q-SNARE, SNAP-25/23/29 subfamily)</td></tr>
<tr><td><strong>Tissue Distribution</strong></td><td>Brain (hippocampus, cortex, cerebellum), neuroendocrine cells</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">ALZHEIMER'S DISEASE</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">Alzheimer's Disease</a></td>
</tr>
<tr>
<td class="label">SciDEX Hypotheses</td>
<td><a href="/hypothesis/h-73e29e3a" style="color:#ce93d8" title="Score: 0.34">Synaptic Vesicle Tau Capture Inhibition...</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">242 edges</a></td>
</tr>
</table>
</div>

Structure

SNAP-25 has a distinctive architecture optimized for its role as a membrane-anchored t-SNARE[@sutton1998]:

Primary Structural Regions

• N-terminal region (residues 1-84): Extended coiled-coil forming the first SNARE motif
• Central cysteine-rich domain (residues 85-92): Four palmitoylated cysteines anchoring the protein to membrane
• C-terminal region (residues 93-206): Second SNARE motif forming the coiled-coil bundle

SNARE Motifs

SNAP-25 contributes two α-helical SNARE motifs (SN1 and SN2) to the four-helix SNARE bundle:

| Motif | Residues | Role |
|-------|----------|------|
| SN1 (N-terminal) | 19-83 | Forms the first helix of the SNARE bundle; contains the Q-loop |
| SN2 (C-terminal) | 141-202 | Forms the second helix; completes the t-SNARE core |

This is distinct from VAMP2 (which contributes one helix) and syntaxin-1 (one helix), making SNAP-25 unique as the only SNARE protein contributing two helices.

Membrane Anchoring

SNAP-25 is the only SNARE protein without a transmembrane domain:

• Four cysteine residues (Cys 85, 88, 90, 92) are palmitoylated
• Palmitoylation creates a hydrophobic patch that associates with the inner leaflet of the plasma membrane
• The anchoring is reversible — depalmitoylation releases SNAP-25 from the membrane, regulating SNARE complex availability

Isoforms

| Isoform | Expression | Distribution |
|---------|-----------|--------------|
| SNAP-25a | Ubiquitous | Throughout the nervous system |
| SNAP-25b | Brain-enriched | Highest in hippocampus and cortex |

Post-Translational Modifications

• Palmitoylation: Reversible, regulates membrane association and SNARE complex assembly[@pantano2017]
• Phosphorylation: PKC phosphorylates Ser187, reducing release probability and regulating short-term plasticity[@rosenmund2003]
• Oxidation: [Reactive oxygen species](/entities/reactive-oxygen-species) can modify cysteine residues, disrupting palmitoylation and membrane association

Normal Function

Synaptic Vesicle Exocytosis

SNAP-25 is essential for Ca²⁺-triggered neurotransmitter release[@sdhof2013]:

Vesicle Priming

• SNAP-25 recruits synaptic vesicles to release sites at the active zone
• It interacts with Munc18 and Munc13 to form the primed SNARE complex
• Primed vesicles are held in a fusion-ready state by the partial SNARE complex

Neurotransmitter Release

• SNAP-25 is required for quantal content release
• Loss of SNAP-25 severely impairs synchronous release
• Asynchronous release is partially preserved

Synaptic Plasticity

SNAP-25 is a hub for synaptic plasticity modulation[@rosenmund2003]:

• PKC Phosphorylation: Ser187 phosphorylation by PKC reduces SNARE complex stability
• Short-Term Plasticity: PKC-dependent SNAP-25 modulation affects paired-pulse ratio
• Long-Term Potentiation: Activity-dependent SNAP-25 phosphorylation contributes to LTP
• Homeostatic Scaling: Chronic activity changes alter SNAP-25 expression and palmitoylation

Regional and Cellular Distribution

• Brain Regions: Highest expression in [hippocampus](/brain-regions/hippocampus), cerebral [cortex](/brain-regions/cortex), cerebellar cortex
• Cell Types: Excitatory glutamatergic and inhibitory GABAergic [neurons](/entities/neurons)
• Subcellular: Concentrated at the presynaptic active zone and synaptic vesicle membranes

Role in Neurodegenerative Diseases

Alzheimer's Disease

SNAP-25 dysfunction contributes to synaptic failure in AD[@zhang2015]:

Synaptic Loss

• Post-mortem AD brains show reduced SNAP-25 protein levels in the hippocampus and cortex[@rao2012]
• SNAP-25 loss correlates with cognitive decline (MMSE scores) and Braak staging
• CSF SNAP-25 fragments serve as a biomarker of synaptic degeneration[@kelley2016]

• [Aβ oligomers](/proteins/amyloid-beta) impair SNAP-25/syntaxin-1/VAMP2 interactions in lipid mixing assays
• Aβ disrupts SNAP-25 palmitoylation and membrane association
• This reduces the pool of fusion-competent t-SNARE complexes

• Aβ treatment reduces the stability of the ternary SNARE complex
• Impaired SNARE assembly reduces release probability
• Synaptic vesicles fail to fuse efficiently, reducing neurotransmitter release

• SNAP-25 cleavage fragments in CSF indicate synaptic degeneration
• CSF SNAP-25 complements Aβ42 and [tau](/proteins/tau) biomarkers for AD diagnosis
• Longitudinal SNAP-25 changes track cognitive decline progression

Parkinson's Disease

SNAP-25 dysfunction contributes to dopaminergic terminal vulnerability in PD[@ginovart2012]:

Striatal Terminal Deficits

• Reduced SNAP-25 protein in striatal terminals of PD models
• Loss of dopaminergic terminals reduces vesicular dopamine content
• Impaired SNAP-25 function reduces the efficiency of dopamine release

• [α-Synuclein](/proteins/alpha-synuclein) may interfere with SNAP-25 SNARE complex assembly
• α-Syn overexpression reduces SNAP-25 mobility at the active zone
• This contributes to the dopamine release deficit in PD

• Enhancing SNAP-25 function could improve synaptic transmission in early PD
• Stabilizing the SNAP-25/SNARE complex is a therapeutic strategy

Amyotrophic Lateral Sclerosis (ALS)

Motor Nerve Terminals

• Impaired SNAP-25-dependent exocytosis at motor nerve terminals
• Defects in presynaptic function at the neuromuscular junction (NMJ)
• Altered SNAP-25 expression in ALS spinal cord motor neurons

• TDP-43 pathology affects SNAP-25 expression in motor neurons
• Synaptic dysfunction may be an early event in ALS progression
• SNAP-25 as a potential biomarker for motor neuron disease

Schizophrenia

SNAP25 gene polymorphisms are linked to schizophrenia risk[@barr2000]:

• Specific SNAP25 haplotypes increase susceptibility
• SNAP25 variants affect working memory and cognitive function
• Altered SNAP-25 in prefrontal cortex may contribute to psychotic symptoms

Diagnostic and Biomarker Applications

Cerebrospinal Fluid Biomarker

SNAP-25 fragments in CSF indicate synaptic degeneration[@kelley2016]:

• AD Diagnosis: CSF SNAP-25 complements Aβ42 and tau biomarkers
• Disease Progression: Longitudinal changes track cognitive decline
• Sensitivity: SNAP-25 changes appear early in disease course

Brain Imaging

• PET Tracers: SNAP-25-targeted PET agents are under development
• Synaptic Density: SNAP-25 expression correlates with synaptic density measures

Therapeutic Monitoring

• SNAP-25 levels may serve as a pharmacodynamic marker for drugs targeting synaptic function
• Changes in CSF SNAP-25 reflect treatment effects on synaptic integrity

Therapeutic Targeting

| Approach | Mechanism | Status | Indication |
|----------|-----------|--------|------------|
| Botulinum Toxin A | Cleaves SNAP-25 | FDA-approved | Dystonia, spasticity, migraines |
| Botulinum Toxin C | Cleaves SNAP-25 | Research | Experimental therapeutic |
| SNAP-25 Enhancers | Increase expression and function | Preclinical | AD, PD |
| PKC Modulators | Regulate Ser187 phosphorylation | Preclinical | Modulate release probability |
| SNARE Complex Stabilizers | Enhance SNAP-25-Syntaxin-1-VAMP2 interaction | Research | Neuroprotection |

Gene Therapy Approaches

• AAV-SNAP25: Enhancing SNAP-25 expression to restore synaptic function in neurodegeneration
• Palmitoylation Modulators: Enhancing SNAP-25 membrane association
• Splice-Modulating: Targeting disease-specific SNAP25 splice variants

Botulinum Neurotoxin Mechanism

Botulinum neurotoxins (BoNT/A, BoNT/C) cleave SNAP-25 at distinct sites:

• BoNT/A cleaves SNAP-25 at the C-terminal region (residue 197)
• BoNT/C cleaves at the N-terminal region (residue 253 in the longer isoform)
• Cleavage prevents SNAP-25 from forming the SNARE complex
• This blocks acetylcholine release, producing muscle paralysis
• Therapeutic use: Dystonia, spasticity, chronic pain, chronic migraine

Cross-Links

• [SNAP25 Gene](/genes/snap25)
• [VAMP2 Protein](/proteins/vamp2-protein)
• [Syntaxin-1A Protein](/proteins/stx1a-protein)
• [Synaptotagmin-1 Protein](/proteins/syt1-protein)
• [Alpha-Synuclein Protein](/proteins/alpha-synuclein)
• [Amyloid-Beta Protein](/proteins/amyloid-beta)
• [SNARE Complex](/mechanisms/snare-complex)
• [Synaptic Vesicle Cycle](/mechanisms/synaptic-vesicle-cycle)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [ALS](/diseases/amyotrophic-lateral-sclerosis)

External Links

• [UniProt: SNAP-25 (P60880)](https://www.uniprot.org/uniprot/P60880)
• [PDB: SNAP-25 (1KTH)](https://www.rcsb.org/structure/1KTH)
• [NCBI Gene: SNAP25](https://www.ncbi.nlm.nih.gov/gene/6616)